Fulgent Genetics reports Q3 EPS 31c, consensus (15c)

Reports Q3 revenue $71.74M, consensus $71.72M. Ming Hsieh, chairperson of the board of directors and CEO, said, “We continue to see good momentum in our business, with Laboratory Services fueling our initiatives and exhibiting sequential growth in all three areas of our Laboratory Services business for the quarter. In Therapeutics Development, we are encouraged by the preliminary results we are seeing from initial patients being treated in our Phase 2 clinical trial of FID-007 in Head and Neck Cancer, and we continue to move our next candidate, FID-022, through preclinical studies toward an Investigational New Drug (IND) application.”